{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Iovance Biotherapeutics, Inc."},"Symbol":{"label":"Symbol","value":"IOVA"},"Address":{"label":"Address","value":"825 INDUSTRIAL ROAD,SUITE 400, SAN CARLOS, California, 94070, United States"},"Phone":{"label":"Phone","value":"+1 650 260-7120"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma."},"CompanyUrl":{"label":"Company Url","value":"https://www.iovance.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Brian Shew","title":"SVP & Head-Information Technology"},{"name":"Frederick G. Vogt","title":"President, CEO, Secretary & Director"},{"name":"Friedrich Graf Finckenstein","title":"Chief Medical Officer"},{"name":"Hequn Yin","title":"Senior Vice President-Research"},{"name":"Igor P. Bilinsky","title":"Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}